Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;47(7):932-939.
doi: 10.1111/jcpt.13623. Epub 2022 Mar 7.

Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience

Mar Ronda  1 , Sandra Pérez-Recio  1 , Mònica González Laguna  2 , Maria de la Fe Tubau Quintano  3   4 , Josep Llop Talaveron  2 , Laura Soldevila-Boixader  1 , Jordi Carratalà  1   5 , Guillermo Cuervo  1 , Ariadna Padullés  2   5
Affiliations

Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience

Mar Ronda et al. J Clin Pharm Ther. 2022 Jul.

Abstract

Objective: To evaluate the real-world clinical efficacy of ceftolozane/tazobactam (C/T) in difficult-to-treat infections caused by multi-drug resistant Gram-negative microorganisms, including carbapenem-resistant Pseudomonas aeruginosa.

Methods: Retrospective cohort study of adult patients treated with C/T for at least 48 hours for infections caused by multi-drug resistant Gram-negative bacteria in a tertiary hospital from May 2016 until August 2019. The primary outcome analysed was clinical failure, defined as a composite of symptomatology persistence after 7 days of C/T treatment, infection recurrence, and/or all-cause mortality within 30 days of follow-up.

Results and discussion: 96 episodes of C/T treatment were included, mostly consisting of targeted treatments (83.9%) for the following sources of infection: intra-abdominal (22.6%), urinary tract (25.8%), skin and soft tissue (19.4%), hospital-acquired pneumonia (14%), and other (6.4%). The most frequently isolated bacteria were carbapenem-resistant (88, 94.6%). Clinical failure rate was 30.1%, due to persistent infection at day 7 (4.3%), recurrence of the initial infection (16.1%), or 30-day all-cause mortality (8.6%). Adverse events most frequently reported were Clostridium difficile infection (9%) and cholestasis (8%).

What is new and conclusion: C/T showed a favourable clinical profile for difficult-to-treat multidrug-resistant and carbapenem-resistant Gram-negative infections, regardless of the source of infection.

Keywords: MDR microorganisms; carbapenem-resistant; ceftolozane/tazobactam; difficult-to-treat infections.

PubMed Disclaimer

References

REFERENCE

    1. Roca I, Akova M, Baquero F, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22-29. 10.1016/j.nmni.2015.02.007
    1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277-283.
    1. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):1-61. 10.1128/CMR.00115-20
    1. FDA US-Food and Drug Administration. ZERBAXA. Prescr Inf. Published Online. 2014;1-25.
    1. Dietl B, Sánchez I, Arcenillas P, et al. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes. Int J Antimicrob Agents. 2018;51(3):498-502. 10.1016/j.ijantimicag.2017.11.003

LinkOut - more resources